Citations

Showing 10 of 107969 citations.

Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis
Poshusta, Tanya L., Katoh, Nagaaki , Dispenzieri, Angela , Ramı́rez-Alvarado, Marina , Gertz, Morie A. , Dispenzieri, Angela , Ramirez-Alvarado, Marina

Mayo Clinic

International Journal of Molecular Sciences | November 15, 2013 | Volume: 14 | Issue: 11 | Pages: 22604-22617

10.3390/ijms141122604 | PMID 24248061 Get It

Light chain (AL) amyloidosis is a devastating disease characterized by amyloid deposits formed by immunoglobulin light chains. Current available treatments involve conventional chemotherapy and autologous stem cell transplant. We have recently concluded a phase III trial comparing these two treatments. AL amyloidosis patients who achieve hematological complete response (CR) do not necessarily achieve organ response regardless of the treatment they received. In order to investigate the possible correlation between amyloid formation kinetics and organ response, we selected AL amyloidosis patients from the trial with kidney involvement and CR after treatment. Six patients were selected and their monoclonal immunoglobulin light chains were characterized. The proteins showed differences in their stability and their kinetics of amyloid formation. A correlation was detected at pH 7.4, showing that less stable proteins are more likely to form amyloid fibrils. AL-T03 is too unstable to form amyloid fibrils at pH 7.4. This protein was found in the only patient in the study that had organ response, suggesting that partially folded species are required for amyloid formation to occur in AL amyloidosis.
Editorial Comment
Husmann, Douglas A. , Husmann, Douglas

Mayo Clinic

Journal of Urology | November 15, 2013 | Volume: 191 | Issue: 2 | Pages: 450-450

10.1016/j.juro.2013.08.121 | PMID 24239864 Get It

LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner
Ohkawara, Bisei , Cabrera‐Serrano, Macarena , Nakata, Tomohiko, Milone, Margherita , Asai, Nobuyuki, Ito, Kenyu , Ito, Yasutomo, Engel, Andrew G. , Ohno, Kinji , Ito, Mikako , Masuda, Akio

Mayo Clinic

Human Molecular Genetics | November 15, 2013 | Volume: 23 | Issue: 7 | Pages: 1856-1868

10.1093/hmg/ddt578 | PMID 24234652 Get It

Abstract Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Using Sanger and exome sequencing in a CMS patient, we identified two heteroallelic mutations, p.Glu1233Lys and p.Arg1277His, in LRP4 coding for the postsynaptic low-density lipoprotein receptor-related protein 4. LRP4, expressed on the surface of the postsynaptic membrane of the neuromuscular junction, is a receptor for neurally secreted agrin, and LRP4 bound by agrin activates MuSK. Activated MuSK in concert with Dok-7 stimulates rapsyn to concentrate and anchor AChR on the postsynaptic membrane and interacts with other proteins implicated in the assembly and maintenance of the neuromuscular junction. LRP4 also functions as an inhibitor of Wnt/beta-catenin signaling. The identified mutations in LRP4 are located at the edge of its 3rd beta-propeller domain and decrease binding affinity of LRP4 for both MuSK and agrin. Mutations in the LRP4 3rd beta-propeller domain were previously reported to impair Wnt signaling and cause bone diseases including Cenani–Lenz syndactyly syndrome and sclerosteosis-2. By analyzing naturally occurring and artificially introduced mutations in the LRP4 3rd beta-propeller domain, we show that the edge of the domain regulates the MuSK signaling whereas its central cavity governs Wnt signaling. We conclude that LRP4 is a new CMS disease gene and that the 3rd beta propeller domain of LRP4 mediates the two signaling pathways in a position-specific manner.
H alomonas sulfidaeris ‐dominated microbial community inhabits a 1.8 km‐deep subsurface C ambria
Dong, Yiran , Kumar, Charu G., Kim, Pan‐Jun , Miller, P., Price, Nathan D. , Flynn, Theodore M. , Sanford, Robert A. , Krapac, Ivan G., Locke, Randall A. , Hong, Pei‐Ying , Tamaki, Hideyuki , Mackie, Roderick I. , Hernandez, Alvaro G. , Wright, Chris , Mikel, Mark A. , Walker, Jared, Sivaguru, Mayandi , Fried, Glenn , Yannarell, Anthony C. , Fouke, Bruce W. , Chia, Nicholas , Cann, Isaac , Liu, Wen‐Tso , Price, Nathan D

Mayo Clinic

Environmental Microbiology | November 14, 2013 | Volume: 16 | Issue: 6 | Pages: 1695-1708

10.1111/1462-2920.12325 | PMID 24238218 Get It

Summary A low‐diversity microbial community, dominated by the γ ‐proteobacterium H alomonas sulfidaeris , was detected in samples of warm saline formation porewater collected from the C ambrian Mt. S imon S andstone in the I llinois B asin of the N orth A merican M idcontinent (1.8 km/5872 ft burial depth, 50° C , pH 8, 181 bars pressure). These highly porous and permeable quartz arenite sandstones are directly analogous to reservoirs around the world targeted for large‐scale hydrocarbon extraction, as well as subsurface gas and carbon storage. A new downhole low‐contamination subsurface sampling probe was used to collect in situ formation water samples for microbial environmental metagenomic analyses. Multiple lines of evidence suggest that this H . sulfidaeris ‐dominated subsurface microbial community is indigenous and not derived from drilling mud microbial contamination. Data to support this includes V 1‐ V 3 pyrosequencing of formation water and drilling mud, as well as comparison with previously published microbial analyses of drilling muds in other sites. Metabolic pathway reconstruction, constrained by the geology, geochemistry and present‐day environmental conditions of the Mt . S imon S andstone, implies that H . sulfidaeris ‐dominated subsurface microbial community may utilize iron and nitrogen metabolisms and extensively recycle indigenous nutrients and substrates. The presence of aromatic compound metabolic pathways suggests this microbial community can readily adapt to and survive subsurface hydrocarbon migration.
Paraneoplastic and Autoimmune Encephalopathies
Clardy, Stacey , Quek, Amy Lin, O’Toole, Orna , O'Toole, Orna, Quek, Amy M.L. , Clardy, Stacey L

Mayo Clinic

Seminars in Neurology | November 14, 2013 | Volume: 33 | Issue: 04 | Pages: 357-364

10.1055/s-0033-1359318 | PMID 24234357 Get It

Primary Progressive Aphasia and Apraxia of Speech
Jung, Youngsin, Josephs, Keith A. , Duffy, Joseph R.

Mayo Clinic

Seminars in Neurology | November 14, 2013 | Volume: 33 | Issue: 04 | Pages: 342-347

10.1055/s-0033-1359317 | PMID 24234355 Get It

Revisiting the framework of the National Institute on Aging‐Alzheimer's Association diagnostic criteria
Carrillo, María C. , Dean, Robert A., Nicolas, François, Berman, Robert , Khachaturian, Zaven S., Bain, Lisa J. , Schindler, Rachel, Miller, David S. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | November 14, 2013 | Volume: 9 | Issue: 5 | Pages: 594-601

10.1016/j.jalz.2013.05.1762 | PMID 24007744 Get It

Abstract In 2011, the National Institute on Aging and the Alzheimer's Association (NIA‐AA) proposed revising the criteria for diagnosing Alzheimer's disease (AD), which had been established more than 25 years earlier by the National Institute on Neurologic and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA), now called the Alzheimer's Association. The NIA‐AA initiative also built upon research criteria for AD proposed by the International Working Group (IWG) in 2007 and updated in 2010. These efforts to revise the criteria reflect the need to improve diagnostic accuracy, facilitate clinical trials, and establish a common set of criteria that are universally accepted across domains of clinical practice, research, and drug development. To ensure that the proposed NIA‐AA criteria remain as current as possible, the Alzheimer's Association Research Roundtable convened a meeting in Washington, DC, on October 1 and 2, 2012, bringing together international stakeholders from industry, academia, and regulatory agencies to identify areas of agreement and research gaps respective of NIA‐AA criteria and IWG recommendations.
Narrowband Ultraviolet B Light in Langerhans Cell Histiocytosis: A Case Report
Ness, Molly J., Lowe, Garrett C., Hand, Jennifer L. , Davis, Dawn Marie R.

Mayo Clinic

Pediatric Dermatology | November 14, 2013 | Volume: 31 | Issue: 1 | Pages: No page available

10.1111/pde.12240 | PMID 24224945 Get It

AbstractLangerhans cell histiocytosis (LCH) (previously called eosinophilic granuloma, Hand–Schüller–Christian syndrome, Letterer–Siwe disease, and Hashimoto–Pritzker disease) is a rare, heterogeneous disorder with highly variable presentation. LCH commonly affects the skin, as well as internal organs. Because the skin lesions appear benign, and LCH is unfamiliar to most physicians, diagnosis is often delayed. Treatment is controversial, with further clinical study needed. For persons with extensive, skin‐limited disease, the existing topical therapies are impractical. We present a child with cutaneous LCH lesions that responded to ultraviolet light phototherapy with minimal adverse effects or patient discomfort.
Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance
Kumar, Shaji , Jacques, Richard , Ng, Alvin C., McCready, Louise K., Farr, Joshua N. , Zhang, Wei Yan , Rajkumar, S. Vincent , Drake, Matthew T.

Mayo Clinic

Blood | November 14, 2013 | Volume: 123 | Issue: 5 | Pages: 647-649

10.1182/blood-2013-05-505776 | PMID 24227822 Get It

Key PointsMGUS patients have significantly increased cortical bone porosity and reduced bone strength relative to matched controls.
Inflammatory Abdominal Aortic Aneurysm
Ketha, Siva S., Warrington, Kenneth J. , McPhail, Ian R., Warrington, Kenneth J

Mayo Clinic

Vascular and Endovascular Surgery | November 13, 2013 | Volume: 48 | Issue: 1 | Pages: 65-69

10.1177/1538574413510616 | PMID 24226790 Get It

We report a case of an abdominal aortic aneurysm (AAA) that underwent inflammatory transformation which we treated medically with corticosteroids. Medical therapy resulted in resolution of presenting symptoms and observed inflammatory changes. We review the clinical features, associated pathology, diagnostic, and therapeutic options in the management of inflammatory AAA.